300
Participants
Start Date
January 23, 2017
Primary Completion Date
November 23, 2019
Study Completion Date
March 31, 2023
Viaskin Peanut 250µg
DBV712 250 µg, once daily
Jaffe Food Allergy Institute, New York
Children's Hospital of Pittsburgh, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Johns Hopkins Hospital, Baltimore
The University of North Carolina - Chapell Hill, Chapel Hill
Cincinnati Children's Hospital Medical Center, Cincinnati
Ann & Robert Lurie Children's Hospital of Chicago, Chicago
Arkansas Children's Hospital, Little Rock
Baylor College of Medicine - Texas Children's Hospital, Houston
Children's Hospital Colorado, Aurora
National Jewish Health, Denver
Universitätsklinikum Erlangen, Erlangen
University of California, Rady Children's Hospital, San Diego
Stanford University School of Medicine, Stanford
ASTHMA, Inc., Seattle
Massachusetts General Hospital, Boston
Boston Childrens' Hospital, Boston
Children's Medical Center of Dallas, Dallas
Allergy Medical, Brisbane
Princess Margaret Hospital for Children, Perth
Children's Hospital Westmead, Sydney
Clinical Investigations Unit, Cork
Our Lady's Children's Hospital, Dublin
British Columbia Children's Hospital, Vancouver
Cheema Research Inc., Mississauga
Ottawa Allergy Asthma Research Institute, Ottawa
Gordon Sussman Clinical Research Inc., Toronto
CHUM & CHU Sainte-Justine, Montreal
Centre de Recherche Appliquée en Allergie de Quebec, Québec
Charité Universitätsmedizin Berlin, Berlin
St.-Marien-Hospital, Bonn
Lead Sponsor
DBV Technologies
INDUSTRY